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Abstract
Objective Several small published case reports have
suggested that selective serotonin reuptake inhibitors
(SSRIs) can cause night sweats. The purpose of this study
was to investigate this possibility further and to explore
possible associations between night sweats and other
commonly prescribed medications.
Design Cross-sectional, secondary data analysis.
Setting Data were obtained during the Oklahoma Longi-
tudinal Assessment of the Health Outcomes of Mature
Adults, a longitudinal cohort study carried out in the
Oklahoma Physicians Resource/Research Network.
Participants 413 adult primary care patients aged
65–94 years.
Interventions Current regular use of one of 35 classes of
medication.
Main Outcome Measures At least moderate night sweats
during the prior month.
Results A total of 38 (9.2 %) reported night sweats. Age,
gender, body mass index, and total number of medications
taken regularly were not associated with night sweats.
After adjusting for age and gender, SSRIs (odds ratio [OR]
3.01; 95 % confidence interval [CI] 1.26–7.19), angioten-
sin receptor blockers (ARBs) (OR 3.44; 95 % CI
1.36–8.69), and thyroid hormone supplements (OR 2.53;
95 % CI 1.24–5.15) were the only classes of medications
associated with night sweats.
Conclusions Use of SSRIs may well be associated with
night sweats in older patients. Associations found between
night sweats and ARBs and thyroid supplements warrant
further study.
Key Points
The suspected association between selective
serotonin reuptake inhibitors (SSRIs) and night
sweats is supported.
SSRI effects may be common treatable causes of
night sweats in patients seen in primary care.
Associations between thyroid hormone supplements
and angiotensin receptor blockers and night sweats
deserve further study.
Introduction
When asked, 10–14 % of seniors and between 34 and 41 %
of consecutive adults seen in primary care settings in the
USA report experiencing excessive sweating at night [1, 2].
The estimated annual incidence in adults over 65 years of
age is 5 % [3, 4]. The symptom is rarely reported to cli-
nicians, even by those experiencing ‘‘severe’’ night sweats
[1]. In a majority of cases, neither the physician nor the
patient has any credible idea about what is causing the
symptom [1].
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Sweating is a complex process controlled primarily, but
not entirely, by a thermoregulatory center in the hypo-
thalamus. The eccrine sweat glands are innervated pri-
marily by sympathetic neurons that secrete acetyl choline
rather than norepinephrine at their glandular receptor sites.
Both sympathomimetic and cholinergic agents can there-
fore increase sweating. Thermoregulatory sweating is
usually accompanied by vasodilatation, which may also
contribute to sweat production. Many other factors that can
modulate sweating including serum osmolality, circadian
rhythm, environmental conditioning, physical fitness, acute
and chronic anxiety, sleep disturbances, depression, and
hormonal fluctuations (e.g. menopause) [5].
Diaphoresis, in general, is an acknowledged side effect
of a number of medications, including non-steroidal anti-
inflammatory drugs (NSAIDs), narcotics, antiviral agents,
fluoroquinolones, angiotensin-converting enzyme inhibi-
tors (ACEIs), angiotensin receptor blockers (ARBs), cal-
cium channel blockers (CCBs), beta adrenergic blockers,
vasodilators, anti-estrogenic agents, progesterone, testos-
terone, thyroid hormone supplements, corticosteroids,
insulin, oral hypoglycemic agents, calcitonin, proton pump
inhibitors (PPIs), mesalamine, phosphodiesterase inhibi-
tors, tricyclic antidepressants (TCAs), selective serotonin
reuptake inhibitors (SSRIs), neuroleptics, cholinesterase
inhibitors, anxiolytics, and sedative hypnotics [6]. Sweat-
ing is also reported to occur with regular use of inhaled
sympathomimetics, inhaled corticosteroids, and some
ophthalmologic agents [7–9].
A recently published review of the literature on night
sweats found several case studies suggesting that SSRIs
can cause night sweats, and that treatment with alpha
adrenergic blockers, mirtazapine, cyproheptadine, and/or
benztropine might ameliorate them [5, 10–15]. One cross-
sectional study found an association between night sweats
and use of aspirin or acetaminophen [16]. Night sweats also
appear to be associated with younger age, menopause,
fever, panic attacks, sleep problems, muscle cramps, sen-
sory abnormalities (numbness, impaired vision or hearing),
and pain [5]. We retrospectively analyzed data obtained
from older patients enrolled in a longitudinal cohort study
to see whether we could confirm that regular use of SSRIs
was associated with night sweats. We also looked for
possible associations between night sweats and 34 other
categories of medications.
Methods
The data used in these analyses were obtained from par-
ticipants in the Oklahoma Longitudinal Assessment of the
Health Outcomes of Mature Adults (OKLAHOMA Stud-
ies), a longitudinal cohort study conducted in the
Oklahoma Physicians Resource/Research Network (OK-
PRN) from 1999 to 2004. The methods used have been
published in detail previously [3, 17]. Briefly, 834 indi-
viduals aged C65 years were initially recruited from the
billing record lists of 23 family physicians in central
Oklahoma. Patients with known dementia and those living
in nursing homes were excluded.
Each participant completed an annual questionnaire that
included socio-demographic information, health habits,
past and current medical problems, current symptoms, self-
rated health, quality of life, and functional status. A
research nurse reviewed the questionnaires to ensure that
all items were addressed. Participants were re-enrolled
annually for up to 4 years, and the questionnaires and
examinations were repeated each year at the time of
re-enrollment.
The following question about night sweats was included
in the questionnaires: ‘‘During the last month, how much
trouble have you had with night sweats’’? Response options
included ‘‘no trouble, a little trouble, some trouble, a fair
amount of trouble, and a great deal of trouble’’. We con-
verted these responses to a dichotomous variable called
‘‘night sweats’’ (including those reporting some, a fair
amount, or a great deal of trouble with night sweats). Only
responses made in the third year were considered in this
study.
In the third year of the study, participants were asked to
bring in all medications they were currently taking regu-
larly (at least twice a week). The medications were recor-
ded and entered into the database within predetermined
pharmacologic categories. The category ‘analgesics’
included NSAIDs, acetaminophen, narcotics, and combi-
nations of narcotics and acetaminophen. We did not
include aspirin because, in this cohort, aspirin use was
nearly always low dose (81 mg) and presumably not for
analgesia. Categories of medications used by fewer than
ten patients were excluded from the analyses.
Descriptive statistics were calculated for all variables.
Chi squared analyses were used to identify potential
associations between ‘‘night sweats’’ and use of any med-
ications within each of the categories (dichotomous). We
also examined possible associations between night sweats
and potential confounders, including age, gender, body
mass index (BMI), and total number of medications taken.
We then created separate logistic regression models for
each of the medication classes with significant (p \ 0.01)
associations with night sweats in order to adjust for age and
gender. BMI and number of medications used were not
associated with night sweats or with any medication class
and were therefore not included in the regression models.
There was an association between use of an SSRI and use
of an ARB (p = 0.01), but no associations were found
between use of either of these medications and thyroid
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In year three of the OKLAHOMA Studies, 413 patients
aged 65–94 years were enrolled. Their mean (standard
deviation [SD]) age was 74.8 (5.5); 231 (56 %) were
females; 38 (9.2 %) reported night sweats. Each of 35
categories of medications was being taken regularly by at
least ten participants (see Table 1). The mean (SD) number
of different categories of medications taken by participants
was 4.9 (2.7). The median and range were 5 and 0–15.
Associations Between Night Sweats and Medication
Categories
Age, gender, BMI, and number of medications taken reg-
ularly were not associated with night sweats. Bivariate
associations were found between night sweats and regular
use of SSRIs, ARBs, and thyroid hormone supplements but
not for any of the other medication categories examined.
Adjustment for age and gender did not substantially change
these associations. In the adjusted models, patients were
again more likely to have reported night sweats if they used
SSRIs (odds ratio [OR] 3.01; 95 % confidence interval [CI]
1.26–7.19), ARBs (OR 3.44; 95 % CI 1.36–8.69), and/or
thyroid hormone supplements (OR 2.53; 95 % CI
1.24–5.15) (see Table 2).
Discussion
These findings support the previously reported association
between SSRIs and night sweats and raise suspicion that
certain other medication classes, particularly ARBs, and
thyroid hormone supplements might contribute to night
sweats in patients over the age of 65 years.
An estimated 11 % of individuals aged C12 years in the
USA take antidepressant medications, the majority of
whom take SSRIs [18]. Therefore, if SSRIs cause night
sweats, they may be one of the more common causes of
this symptom in primary care patients. SSRIs might cause
night sweats by blocking muscarinic receptors [19] and/or
by increasing noradrenergic release, and there is evidence
that alpha adrenergic blockers can reduce night sweats in
those taking SSRIs [13, 20, 21]. However, it is possible that
it is the underlying depression or anxiety and not the
medications that cause nighttime sweating [3]. We were
unable to find information in the published literature about
how often night sweats occurring in association with SSRIs
require discontinuation, reduction in dosage, or treatment
with a second medication.
Sweating is listed as a possible side effect of ARBs. The
potential mechanism has not been published, to our
knowledge, beyond speculation that it may be due to
peripheral vasodilatation [22–24]. However, it is not clear
Table 1 Number of patients taking medications in each category
(N = 413)
Medication category Percentage taking



































H2B histamine H2 blockers, NSAID non-steroidal anti-inflammatory
drug, PPI protein pump inhibitor, SSRI selective serotonin reuptake
inhibitor
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why this mechanism should induce sweating only at night.
In speculating about possible mechanisms, it is worth
considering which patients are more likely to take ARBs.
For example, ARBs are more likely to be used by indi-
viduals who were unable to tolerate ACEIs because of
cough or angioedema. Perhaps the metabolic idiosyncrasies
associated with those side effects are related to sweating at
night.
Thyroid hormone replacement or supplements can pro-
duce sweating if given in excess, producing a hyperthyroid
state of increased thermogenesis, systemic catecholamine
levels, and/or catecholamine receptor hypersensitivity [25–
28]. Inadvertent overtreatment with synthetic thyroxin, in
particular, might induce sweating. Overtreatment is often
due to reliance on the serum thyroid-stimulating hormone
(TSH) level, which may or may not be a true reflection of
thyroid hormone activity in tissues, especially in the
elderly [29].
The study has several important limitations. First, the
number and proportion of participants reporting night
sweats was small, and the few participants within some of
the medication categories reduced our power to detect
associations with night sweats and those medication clas-
ses. Second, it was a cross-sectional study, precluding us
from drawing firm conclusions about causation. Further,
some potential confounders like depression were not con-
sidered, though there is no reason to believe that the pre-
dictors of night sweats identified in prior studies (e.g. fever,
muscle cramps, and subjective sensory impairments) are
associated with use of SSRIs, ARBs, or thyroid hormones.
Finally, sweating and symptomatic complaints related to
sweating tend to diminish with increasing age. This
response was tested, with thermal stimulation and intra-
dermal acetylcholine or methacholine, in 46 men and
women aged [70 years compared with younger adults
[30]. A higher threshold for sweating was found in most of
the older adults compared with the younger controls, with
an even higher threshold for older women than men. These
findings suggest that a cohort of older people may not be
the best population sample in which to study the associa-
tion of medications with sweating. In addition to possibly
under-representing the sweat-inducing potential of drugs,
older people are more likely to have more medical condi-
tions and take more medications, increasing the unmea-
sured variability in our analyses. However, the fact remains
that prior studies have reported night sweats but failed to
identify or investigate associations between their incidence
and possible drugs that cause them.
Conclusions
The findings of this study are consistent with other pub-
lished evidence that SSRIs are associated with and may
cause night sweats. Because of their frequency of use, this
may be one of the more common causes of night sweats in
patients seen in primary care. The other medication classes
implicated in this study, ARBs and thyroid hormone sup-
plements, deserve further study.
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